You might think that after Michael Brown's FEMA fiasco, the White House would try to avoid any appearance of cronyism in job appointments requiring technical expertise. You might think that after the Plan B contraceptive flap and safety problems with drugs like Vioxx, it would seek to avoid controversy while picking someone to run the embattled Food and Drug Administration (FDA). Think again.
The Administration moved swiftly to name Dr. Andrew von Eschenbach as interim FDA chief after the September departure of Commissioner Lester Crawford just two months after his confirmation. (The Senate is investigating a possible failure to disclose financial interests.)...
To continue reading:
or
Log-In
